MIA PaCa-2
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
MIA PaCa-2 is an epithelial cell line originating from pancreatic tumor tissue of a 65-year-old Caucasian male. This established human pancreatic ductal adenocarcinoma (PDAC) cell line features round and spindle-shaped adherent cells, as well as round floating cells.
These cells are notably large with abundant cytoplasm, displaying a high degree of aneuploidy and a unique propensity to grow on top of neighboring cells, eventually transitioning to free suspension growth. Moreover, MIA PaCa-2 is sensitive to L-Asparaginase, has a doubling time of 40 hours, and exhibits a colony-forming efficiency of 19% when cultivated in soft agar.
Why choose MIA PaCa-2 from AcceGen?
MIA PaCa-2 cells from AcceGen offer high viability and quality, ensuring sterility with rigorous testing for bacteria, fungi, and mycoplasma. Their identity is confirmed through STR profile and HLA type analysis, reflecting AcceGen’s commitment to stringent quality control standards.
| Product Code | MIA-PaCa-2; MIA-PACA-2; MIA-Pa-Ca-2; MIA Paca2; MIA PaCa2; MiaPaCa-2; MIAPACA-2; MiaPaca.2; MiaPaCa2; Miapaca2; MIAPaCa2; MIAPACA2; Mia PACA 2; MIAPaCa-2; PaCa2; MiaPaCa |
| Species | Human |
| Cat.No | ABC-TC5587 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Pancreatic Ductal Adenocarinoma |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
MIA PaCa-2, a versatile cell line derived from pancreatic cancer tissue, serves as a crucial tool in various aspects of pancreatic cancer research. It facilitates the exploration of pancreatic cancer biology, enabling in-depth studies of metastatic potential and resistance to chemoradiotherapy. Additionally, MIA PaCa-2 aids in morphological characterization of human PDAC cell lines, shedding light on the intricate series of alterations cancer cells undergo during the metastatic process. This valuable information not only enhances our understanding of pancreatic ductal adenocarcinoma (PDAC) but also paves the way for the development of innovative PDAC diagnostics and more personalized treatment strategies for individuals affected by this challenging disease.
